Neopharm
Key metrics
Earnings
| Revenue, Q3 2026 | ₩39.4bn |
|---|---|
| Revenue QoQ | -9.6% |
| Revenue YoY | Not available |
| Operating income, Q3 2026 | ₩10.0bn |
| Operating income QoQ | +2.6% |
| Operating income YoY | Not available |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 3 |
|---|---|
| DART filings, previous 3 months | 4 |
Insider transactions
| Open-market buys, last 12 months (shares) | 320,400 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩7.2bn |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 320,400 shares |
| Insiders who bought, last 12 months | 2 |
Insider transactions (last 12 months)
Open-market buys: 320,400 shares (₩7.2bn). Open-market sells: 0 shares (₩0). Net open-market buying: +320,400 shares. Insiders who bought: 2.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | IT'S HANBULCO., LTD (Controlling shareholder) | Open-market buy | +38,885 shares | ₩24,481 | ₩952m | |
| Nov 6, 2026 | IT'S HANBULCO., LTD (Controlling shareholder) | Open-market buy | +121,315 shares | ₩23,469 | ₩2.8bn | |
| May 4, 2026 | IT'S HANBULCO., LTD (Controlling shareholder) | Open-market buy | +60,200 shares | ₩21,840 | ₩1.3bn | |
| Apr 30, 2026 | IT'S HANBULCO., LTD (Controlling shareholder) | Open-market buy | +100,000 shares | ₩20,765 | ₩2.1bn |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩132.2bn | ₩28.8bn |
| 2024 | ₩119.0bn | ₩24.7bn |
| 2023 | ₩97.1bn | ₩25.3bn |